
If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.

If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.

Your daily dose of the clinical news you may have missed.

Women aged 40 to 65 years who had persistent insomnia and poor sleep duration were at a 75% greater risk for incident CVD over 2 decades of follow up.

Acute, preventable diabetes complications days fell by 8.4% among participants enrolled in a preventive drug list benefit and by even more among low-income subscribers.

Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.

Your daily dose of the clinical news you may have missed.

Budesonide oral suspension is the first oral therapy for EoE and represents a needed option in the category, offering flexibility for both patients and clinicians.

Anticoagulation and antiplatelet therapy appeared equally effective in reducing risk of recurrent stroke following cryptogenic stroke in persons with evidence of atrial cardiopathy.

Hospitalization for COVID-19 was associated with higher long-term risks of death, adverse health outcomes, and significant cumulative excess DALYs vs influenza.
Fever and confusion bring the young man in his twenties to the ED; roommates relate he's been weak and flu-like for 5 days. What's your diagnosis?

Get GOLD Report updates at-a-glance on initiating pharmacotherapy, avoiding exacerbations, treating dyspnea, how to approach using ICS, plus other topics.

Your daily dose of the clinical news you may have missed.

Get a quick look at 13 of the many FDA-approved drugs in 2023 for conditions commonly seen in primary care.

Approval of the application would extend the current Arexvy indication for prevention of RSV in adults aged 60 years and older; a June 2024 PDUFA date is set.

Your daily dose of the clinical news you may have missed.

Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.

Results showed nearly one-third of hospitalizations for acute respiratory illness among children aged <5 years were associated with RSV.

Among women with PCOS, the risk for a suicide attempt was highest (by a factor of 9) among young adults aged 20 to 40 years, followed by adolescents.

Your daily dose of the clinical news you may have missed.

Influenza continues to rage in some parts of the US; try these 4 quick questions on vaccines you may or may not have on hand.